Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners

0
138

“Building on the great work of the founders, we have heavily invested in additional complex technologies and expanded manufacturing capabilities,” said Mark Hersee, a partner at BC Partners.

Legal Advisors and Timeline

Goldman Sachs Alternatives is receiving legal counsel from White & Case LLP, Allen & Overy, Shearman & Sterling, and Sullivan & Cromwell LLP. Synthon is represented by Latham & Watkins LLP.

The transaction, expected to close by June 2025, is subject to customary regulatory and closing conditions.

Signup for the USA Herald exclusive Newsletter